TRIAMCINOLONE
Clinical safety rating: avoid
Positive evidence of fetus risks but benefits may outweigh risks in some cases
Synthetic glucocorticoid with anti-inflammatory, immunosuppressive, and anti-allergic effects. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
| Metabolism | Hepatic via cytochrome P450 3A4 (CYP3A4); undergoes reduction, hydroxylation, and conjugation; metabolites are excreted renally. |
| Excretion | Triamcinolone is primarily metabolized hepatically; unchanged drug and metabolites are excreted renally. Approximately 25-30% of a dose is excreted in urine as unchanged triamcinolone, with the remainder as metabolites. Fecal excretion accounts for less than 10%. |
| Half-life | The terminal elimination half-life of triamcinolone is approximately 2-5 hours (mean 3 hours) following intravenous administration. Clinically, this short half-life supports multiple daily dosing for systemic effects, but duration of action is longer due to receptor occupancy. |
| Protein binding | Triamcinolone is approximately 66-78% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin (transcortin). |
| Volume of Distribution | The apparent volume of distribution is approximately 1.3-1.6 L/kg, indicating extensive tissue distribution (total body water exceeds 0.6 L/kg). |
| Bioavailability | Oral: approximately 15-40% due to first-pass metabolism (mean ~23%). Intramuscular: 100% (complete absorption). Topical: variable, typically 0.1-2% for intact skin; higher with damaged skin or occlusive dressings. |
| Onset of Action | Intravenous: immediate (within minutes); intramuscular: 30-60 minutes; oral: 1-2 hours; topical: variable, typically within hours for anti-inflammatory effect; intra-articular: 24-48 hours for relief of joint pain. |
| Duration of Action | The duration of action is dose- and route-dependent. For systemic effects, duration is 12-36 hours after a single IV or IM dose. Intra-articular injections provide relief for weeks (1-4 weeks). Topical effects last 4-12 hours depending on formulation and extent of application. |
Intramuscular: 40-80 mg as a single dose; Intra-articular: 5-40 mg depending on joint size; Topical: Apply thin layer 2-4 times daily; Oral: 4-48 mg/day in divided doses.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. In severe renal impairment (GFR <30 mL/min), use with caution due to increased risk of fluid retention; dose reduction or interval prolongation may be considered. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 25-50% due to impaired metabolism. Child-Pugh C: Avoid use or reduce dose by 50-75% if necessary; monitor for toxicity. |
| Pediatric use | Intramuscular: 0.11-1.6 mg/kg/day in divided doses every 12-24 hours; Oral: 0.1-2 mg/kg/day divided every 6-12 hours; Topical: Apply sparingly 1-2 times daily; not for use in children <2 years except under specialist guidance. |
| Geriatric use | Start at lowest effective dose (e.g., oral 4 mg/day, topical once daily). Monitor for hyperglycemia, osteoporosis, and fluid retention. Avoid prolonged use due to increased risk of adverse effects. Consider dose reduction by 20-30% in frail elderly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
CYP3A4 inducers (eg phenytoin) may decrease efficacy and inhibitors may increase effects Can cause hyperglycemia and adrenal suppression with prolonged use.
| Breastfeeding | Enters breast milk in small amounts; M/P ratio approximately 0.5-1.0 for prednisolone equivalent. American Academy of Pediatrics compatible; use lowest effective dose. No reports of neonatal adrenal suppression from maternal doses <20 mg/day prednisone equivalent. |
| Teratogenic Risk | Pregnancy Category C. First trimester: Increased risk of cleft palate (odds ratio 1.3-3.3) based on human data; avoid use. Second/third trimesters: Risk of fetal adrenal suppression, intrauterine growth restriction, and preterm delivery with prolonged systemic use. Topical use considered low risk but high-potency agents should be limited. |
■ FDA Black Box Warning
None.
| Common Effects | Hyperglycemia |
| Serious Effects |
["Systemic fungal infections (untreated)","Hypersensitivity to triamcinolone or any excipient","Intramuscular administration in idiopathic thrombocytopenic purpura","Live or live-attenuated vaccines (concurrent use)","Ophthalmic use in active herpes simplex keratitis, vaccinia, varicella, mycobacterial infections, or fungal diseases"]
| Precautions | ["Increased risk of infections (bacterial, viral, fungal, protozoan)","Adrenal suppression with prolonged use or abrupt withdrawal","Cushing's syndrome with high doses or long-term use","Osteoporosis with chronic use","Growth suppression in children","Glaucoma and cataracts (especially with ophthalmic use)","Immunosuppression and risk of reactivation of latent infections (e.g., TB, hepatitis B, herpes zoster)","Fluid and electrolyte disturbances (hypernatremia, hypokalemia, edema)","Gastrointestinal perforation (especially in patients with GI disease)","Muscle wasting and myopathy"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, and signs of infection. Fetal growth ultrasound every 4-6 weeks if prolonged use. Neonatal monitoring for adrenal suppression (electrolytes, glucose) if maternal dose >20 mg/day prednisone equivalent for >2 weeks before delivery. |
| Fertility Effects | No known significant adverse effects on fertility in animal studies or human data. May suppress ovulation at high doses via hypothalamic-pituitary-adrenal axis suppression; reversible upon dose reduction. |